Hongxin Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hongxin Pan has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Guang-Nan Luo
Department of Obstetrics and Gynecology, The 3rd Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, 518000, PR China
4 shared publicationsGiulia Spagnol
3 shared publicationsMarco Noventa
3 shared publicationsCarlo Saccardi
2 shared publicationsCheng-Lu Qin
Department of Obstetrics and Gynecology, The 3rd Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, 518000, PR China
2 shared publicationsMatteo Marchetti
2 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 6 (3) , e000483
No specific molecular profile (NSMP) endometrial cancer: from residual category to clinical decision driver
- 26 August 2026
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 6 (3) , e000483
Open AccessNo specific molecular profile (NSMP) endometrial cancer: from residual category to clinical decision driver
- Open Access
- 14 December 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (4) , e000277
New frontiers in the management of recurrent epithelial ovarian cancer: a comprehensive review
Ovarian cancer recurs in approximately 70% of cases. In platinum-sensitive relapse, platinum-based therapy remains the backbone of treatment, with optional integration of secondary cytoreductive surgery achieving complete resection and/or hyperthermic intraperitoneal chemotherapy, although evidence remains conflicting. Bevacizumab combined with chemotherapy improves progression-free survival (PFS) but not overall survival (OS). Poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance significantly prolongs PFS in patients with germline or somatic BRCA mutations; its use is currently restricted to this subgroup. Immune checkpoint inhibitors have failed to demonstrate benefit in phase III trials. In platinum-resistant ovarian cancer (PROC), platinum rechallenge retains activity in selected patients. Bevacizumab with chemotherapy improves PFS without OS benefit. Novel antibody-drug conjugates (ADCs) are emerging as promising options: mirvetuximab soravtansine significantly improved PFS (5.6 vs 4.0 months) and OS (16.5 vs 12.8 months) compared with chemotherapy in folate receptor alpha-high PROC (MIRASOL). Trastuzumab deruxtecan has shown high response rates in HER2-expressing disease. Other ADCs and targeted agents, including the WEE1 inhibitor adavosertib, are currently under evaluation. Biomarker-driven therapies are reshaping the management of recurrent ovarian cancer. Future strategies should prioritise improved patient selection and earlier integration of targeted therapies.
- 14 December 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (4) , e000277
Open AccessNew frontiers in the management of recurrent epithelial ovarian cancer: a comprehensive review
Ovarian cancer recurs in approximately 70% of cases. In platinum-sensitive relapse, platinum-based therapy remains the backbone of treatment, with optional integration of secondary cytoreductive surgery achieving complete resection and/or hyperthermic intraperitoneal chemotherapy, although evidence remains conflicting. Bevacizumab combined with chemotherapy improves progression-free survival (PFS) but not overall survival (OS). Poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance significantly prolongs PFS in patients with germline or somatic BRCA mutations; its use is currently restricted to this subgroup. Immune checkpoint inhibitors have failed to demonstrate benefit in phase III trials. In platinum-resistant ovarian cancer (PROC), platinum rechallenge retains activity in selected patients. Bevacizumab with chemotherapy improves PFS without OS benefit. Novel antibody-drug conjugates (ADCs) are emerging as promising options: mirvetuximab soravtansine significantly improved PFS (5.6 vs 4.0 months) and OS (16.5 vs 12.8 months) compared with chemotherapy in folate receptor alpha-high PROC (MIRASOL). Trastuzumab deruxtecan has shown high response rates in HER2-expressing disease. Other ADCs and targeted agents, including the WEE1 inhibitor adavosertib, are currently under evaluation. Biomarker-driven therapies are reshaping the management of recurrent ovarian cancer. Future strategies should prioritise improved patient selection and earlier integration of targeted therapies.
- Open Access
- 5 December 2024
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 4 (4) , e000112
Lymph node metastasis in advanced ovarian cancer: Squaring the circle?
- 5 December 2024
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 4 (4) , e000112
Open AccessLymph node metastasis in advanced ovarian cancer: Squaring the circle?
- 16 September 2022
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 30 (1) , 3-4
Cervical Adenofibroma Found in Congenital Cervical and Vaginal Aplasia After Uterovaginal Anastomosis
- 16 September 2022
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 30 (1) , 3-4
Cervical Adenofibroma Found in Congenital Cervical and Vaginal Aplasia After Uterovaginal Anastomosis
- 1 November 2021
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 28 (11) , 1806-1807
Laparoscopic Management of Myomectomy Scar Pregnancy after a Cryopreserved Embryo Transfer
- 1 November 2021
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 28 (11) , 1806-1807
Laparoscopic Management of Myomectomy Scar Pregnancy after a Cryopreserved Embryo Transfer
- 1 November 2020
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 27 (7) , 1465-1466
Congenital Separated Uterine Cervix and Body
- 1 November 2020
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 27 (7) , 1465-1466
Congenital Separated Uterine Cervix and Body
- Open Access
- 22 January 2020
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 133 (4) , 388-394
Anxiety symptoms in patients with Mayer-Rokitansky-Küster-Hauser syndrome: a cross-sectional study
Background: As a congenital malformation that results in infertility and an inability to have vaginal intercourse, Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome places a considerable psychological burden on patients, which results in anxiety symptoms. However, only single case studies or a few small to medium-sized cross-sectional studies were identified to focus on anxiety symptoms in MRKH patients. Thus, the aim of this study was to explore the status of anxiety symptoms and the related factors in patients with MRKH syndrome. Methods: This cross-sectional study involving 141 patients with MRKH syndrome and 178 healthy women was conducted from January 2018 to December 2018. All participants were required to complete a demographic questionnaire and the Generalized Anxiety Disorder 7-item scale (GAD-7), Patient Health Questionnaire-9, Eysenck Personality Questionnaire-Revised, Short Scale for Chinese, and Chinese Version of the Female Sexual Function Index. The main outcome was the anxiety symptoms measured by the GAD-7. Main outcome was compared between the MRKH syndrome group and the healthy control group. Then, we explored the related factors by comparing patients with and without anxiety symptoms. Results: Of the respondents, 24.1% experienced moderate to severe anxiety symptoms. Patients with MRKH syndrome manifested more severe anxiety symptoms than healthy women. Negative self-evaluation of femininity (odds ratio [OR] 2.706, 95% confidence interval [CI] 1.010–7.247), neurotic personality traits (OR 1.100, 95% CI 1.029–1.175), and coexisting depressive symptoms (OR 4.422, 95% CI 1.498–13.049) were more prevalent in anxious patients. Conclusion: The findings stress the importance of anxiety symptom screening in MRKH patients and identify patients at risk of anxiety symptoms, providing a possible basis for future intervention.
- 22 January 2020
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 133 (4) , 388-394
Open AccessAnxiety symptoms in patients with Mayer-Rokitansky-Küster-Hauser syndrome: a cross-sectional study
Background: As a congenital malformation that results in infertility and an inability to have vaginal intercourse, Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome places a considerable psychological burden on patients, which results in anxiety symptoms. However, only single case studies or a few small to medium-sized cross-sectional studies were identified to focus on anxiety symptoms in MRKH patients. Thus, the aim of this study was to explore the status of anxiety symptoms and the related factors in patients with MRKH syndrome. Methods: This cross-sectional study involving 141 patients with MRKH syndrome and 178 healthy women was conducted from January 2018 to December 2018. All participants were required to complete a demographic questionnaire and the Generalized Anxiety Disorder 7-item scale (GAD-7), Patient Health Questionnaire-9, Eysenck Personality Questionnaire-Revised, Short Scale for Chinese, and Chinese Version of the Female Sexual Function Index. The main outcome was the anxiety symptoms measured by the GAD-7. Main outcome was compared between the MRKH syndrome group and the healthy control group. Then, we explored the related factors by comparing patients with and without anxiety symptoms. Results: Of the respondents, 24.1% experienced moderate to severe anxiety symptoms. Patients with MRKH syndrome manifested more severe anxiety symptoms than healthy women. Negative self-evaluation of femininity (odds ratio [OR] 2.706, 95% confidence interval [CI] 1.010–7.247), neurotic personality traits (OR 1.100, 95% CI 1.029–1.175), and coexisting depressive symptoms (OR 4.422, 95% CI 1.498–13.049) were more prevalent in anxious patients. Conclusion: The findings stress the importance of anxiety symptom screening in MRKH patients and identify patients at risk of anxiety symptoms, providing a possible basis for future intervention.
- Open Access
- 1 October 2019
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology: X
- Vol. 4, 100089
Detection of de novo genetic variants in Mayer–Rokitansky–Küster–Hauser syndrome by whole genome sequencing
- 1 October 2019
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology: X
- Vol. 4, 100089
Open AccessDetection of de novo genetic variants in Mayer–Rokitansky–Küster–Hauser syndrome by whole genome sequencing